Holen Sie sich die Stockscreener-App
1.33
3.91%
0.05
Handel nachbörslich:
1.35
0.02
+1.50%
Schlusskurs vom Vortag:
$1.28
Offen:
$1.28
24-Stunden-Volumen:
526.24K
Relative Volume:
0.62
Marktkapitalisierung:
$80.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.40M
KGV:
-1.8951
EPS:
-0.7018
Netto-Cashflow:
$-18.84M
1W Leistung:
+8.13%
1M Leistung:
+4.72%
6M Leistung:
+25.47%
1J Leistung:
-22.22%
1-Tages-Spanne:
$1.28
$1.38
1-Wochen-Bereich:
$1.23
$1.38
52-Wochen-Spanne:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Firmenname
MAIA Biotechnology Inc
Sektor
Branche
Telefon
312 416 8592
Adresse
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.33 | 77.82M | 0 | -22.40M | -18.84M | -0.7018 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
MAIA Biotechnology Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Continued Pipeline ProgressCommunity Buy Alerts - Newser
MAIA Biotechnology, Inc. 8-K Filing: Annual Meeting Results, Company Details, and NYSE American Listing - Minichart
MAIA Biotechnology Shareholders Back Board and Auditor Appointments - TipRanks
Maia Biotechnology shareholders re-elect directors and ratify auditor at annual meeting - Investing.com
MAIA Biotechnology (MAIA) investors back 2026 directors and auditor at meeting - Stock Titan
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
MAIA Biotechnology (MAIA) Flat at $1.26 — Consolidation Continues 2026-05-18Beta Signals - newser.com
MAIA (NASDAQ: MAIA) Solas Capital and F. T. Golden report 7.1% ownership - Stock Titan
MAIA Biotechnology Ends ATM Stock Offering Agreement - TipRanks
Maia BiotechnologyTo Terminate At The Market Offering Agreement Effective May 23, 2026SEC Filing - TradingView
MAIA Biotechnology (MAIA) halts ATM share sales and terminates program - Stock Titan
MAIA (NYSE American) terminates ATM with H.C. Wainwright after $5.68M raised - Stock Titan
TradingKey - TradingKey
MAIA Biotechnology (NYSEAMERICAN:MAIA) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
MAIA Biotechnology (MAIA) delivers Q4 earnings beat, cutting losses by 32% as clinical pipeline advances.Market Expert Watchlist - Newser
MAIA Biotechnology, Inc. 1Q 2026: Net income $(6.37M), EPS $(0.14) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) boosts cash with $33M raise as NSCLC trials advance - Stock Titan
MAIA Biotechnology | 424B5: Prospectus - Moomoo
Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Rises By 23.0% - MarketBeat
MAIA Biotechnology (MAIA) Projected to Post Quarterly Earnings on Friday - MarketBeat
MAIA Biotechnology (MAIA) price target increased by 18.16% to 12.38 - MSN
MAIA Should I Buy - Intellectia AI
BREAKING: TRUMP JUST BOUGHT THIS STOCK! (01ajqP9sss) - fathomjournal.org
MAIA Biotechnology (MAIA) posts narrower Q4 2025 loss than analyst estimates, lifting shares 4.44 percent today.Pre Earnings - newser.com
MAIA Biotechnology | 8-K: Current report - Moomoo
MAIA Biotechnology (MAIA) Stock Ask Wall (Investor Interest) 2026-04-20Most Watched Stocks - Newser
MAIA Biotechnology opens first U.S. site for lung cancer trial By Investing.com - Investing.com Australia
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Update - MarketBeat
MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com
MAIA Expands THIO-101 Lung Cancer Trial in U.S. - TipRanks
MAIA Biotechnology activates first U.S. site for THIO-101 Phase 2 expansion, NIH funds $2.3M - TradingView
MAIA Biotechnology Activates First U.S. Site for THIO-101 Phase 2 Trial, Reporting Promising Efficacy in Advanced NSCLC Treatment - Quiver Quantitative
Form 8-KCurrent report - ADVFN
MAIA Biotechnology Activates First U.S. Site for Ongoing - GlobeNewswire
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity - Stock Titan
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan
EPS Watch: How do insiders feel about MAIA Biotechnology IncMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Aug Drivers: How does MAIA Biotechnology Inc compare to its peersMarket Risk Summary & Real-Time Sentiment Analysis - baoquankhu1.vn
Value Recap: Is MAIA Biotechnology Inc trading at a discountLayoff News & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Short Covering: Is MAIA Biotechnology Inc stock forming a cup and handle2026 Sector Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is MAIA Biotechnology Inc stock forming a cup and handle - baoquankhu1.vn
Is MAIA Biotechnology (MAIA) Stock Slowing Down | Price at $1.25, Up 4.58%Triple EMA - Newser
Day Trade: What are the future prospects of MAIA Biotechnology IncBond Market & AI Optimized Trade Strategies - baoquankhu1.vn
MAIA Biotechnology Raises $33M to Fully Fund Pivotal Phase 3 Trial of Ateganosine for Advanced NSCLC Treatment - Minichart
Earnings Recap: Is MAIA Biotechnology Inc in a long term uptrend2026 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MAIA Fully Funds Pivotal Phase 3 THIO-104 NSCLC Trial - TipRanks
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy - The Manila Times
MAIA Biotechnology says $33M raise should fully fund pivotal Phase 3 trial of ateganosine - TradingView
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan
MAIA Biotechnology Expects Recent $33 Million Capital Raise - GlobeNewswire
Finanzdaten der MAIA Biotechnology Inc-Aktie (MAIA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
Kapitalisierung:
|
Volumen (24h):